SI2887953T1 - IMPROVED DAPTOMICINE FORMATION FORMULATION - Google Patents

IMPROVED DAPTOMICINE FORMATION FORMULATION Download PDF

Info

Publication number
SI2887953T1
SI2887953T1 SI201330908T SI201330908T SI2887953T1 SI 2887953 T1 SI2887953 T1 SI 2887953T1 SI 201330908 T SI201330908 T SI 201330908T SI 201330908 T SI201330908 T SI 201330908T SI 2887953 T1 SI2887953 T1 SI 2887953T1
Authority
SI
Slovenia
Prior art keywords
daptomycin
formulation
hydrolyzate
stable
lyophilized
Prior art date
Application number
SI201330908T
Other languages
English (en)
Slovenian (sl)
Inventor
Satya Srinivas Chetlapalli
Srirama Sarveswara Rao Mandavilli
Babu Justin
Sathyanarayan Srinivas Meda
Original Assignee
Mylan Laboratories Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mylan Laboratories Limited filed Critical Mylan Laboratories Limited
Publication of SI2887953T1 publication Critical patent/SI2887953T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SI201330908T 2012-08-23 2013-08-22 IMPROVED DAPTOMICINE FORMATION FORMULATION SI2887953T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2452MU2012 2012-08-23
EP13838871.5A EP2887953B1 (en) 2012-08-23 2013-08-22 Improved daptomycin injectable formulation
PCT/IN2013/000511 WO2014045296A2 (en) 2012-08-23 2013-08-22 Improved daptomycin injectable formulation

Publications (1)

Publication Number Publication Date
SI2887953T1 true SI2887953T1 (en) 2018-02-28

Family

ID=54187094

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201330908T SI2887953T1 (en) 2012-08-23 2013-08-22 IMPROVED DAPTOMICINE FORMATION FORMULATION

Country Status (12)

Country Link
US (1) US20150216928A1 (https=)
EP (2) EP3287138A1 (https=)
JP (1) JP2015526463A (https=)
AU (2) AU2013319737B2 (https=)
BR (1) BR112015003198A2 (https=)
CA (1) CA2881121A1 (https=)
DK (1) DK2887953T3 (https=)
ES (1) ES2655215T3 (https=)
NO (1) NO2887953T3 (https=)
PT (1) PT2887953T (https=)
SI (1) SI2887953T1 (https=)
WO (1) WO2014045296A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1207006A1 (en) 2012-09-11 2016-01-22 Hospira Australia Pty Ltd Daptomycin formulations and uses thereof
US10933019B2 (en) 2016-10-21 2021-03-02 Xellia Pharmaceuticals Aps Liquid formulations of daptomycin
CN118766886A (zh) 2017-08-31 2024-10-15 埃克斯利亚制药有限公司 达托霉素制剂
AU2021233893A1 (en) 2020-03-12 2022-08-25 Baxter Healthcare Sa Daptomycin formulations containing a combination of sorbitol and mannitol
CN112684043A (zh) * 2020-12-16 2021-04-20 南京健友生化制药股份有限公司 一种达托霉素有关物质的检测方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4537717A (en) 1982-05-21 1985-08-27 Eli Lilly And Company Derivatives of A-21978C cyclic peptides
FR2657526B1 (fr) * 1990-01-31 1994-10-28 Lvmh Rech Utilisation d'un phosphate d'alpha-tocopherol, ou de l'un de ses derives, pour la preparation de compositions cosmetiques, dermatologiques, ou pharmaceutiques; compositions ainsi obtenues.
WO1997014705A1 (fr) * 1995-10-17 1997-04-24 Showa Denko K.K. Phosphates de tocopherol tres purs, procedes de preparation, techniques d'analyse et produits cosmetiques correspondants
JP4088597B2 (ja) * 2004-01-06 2008-05-21 樹男 飯田 内服および注射用組成物とその製法
CA2564180A1 (en) * 2004-04-22 2005-11-03 Dainippon Sumitomo Pharma Co., Ltd. Pharmaceutical preparation containing bacterial cell wall skeleton component
NZ565049A (en) * 2005-06-17 2012-02-24 Vital Health Sciences Pty Ltd A carrier comprising one or more DI and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof
CA2772660A1 (en) * 2009-09-01 2011-03-10 Northwestern University Delivery of therapeutic agents using oligonucleotide-modified nanoparticles as carriers
US8431539B2 (en) * 2009-09-17 2013-04-30 Eagle Pharmaceuticals, Inc. Formulations of daptomycin
SG10201407724YA (en) * 2009-11-23 2014-12-30 Cubist Pharm Inc Daptomycin compositions and related methods
ES2999020T3 (en) * 2010-02-05 2025-02-24 Phosphagenics Ltd Carrier comprising non-neutralised tocopheryl phosphate
CA2752784A1 (en) * 2010-09-21 2012-03-21 Xellia Pharmaceuticals Aps Daptomycin formulation

Also Published As

Publication number Publication date
US20150216928A1 (en) 2015-08-06
EP2887953A2 (en) 2015-07-01
AU2013319737A1 (en) 2015-02-05
ES2655215T3 (es) 2018-02-19
AU2018204334A1 (en) 2018-07-05
EP2887953A4 (en) 2016-05-25
JP2015526463A (ja) 2015-09-10
DK2887953T3 (en) 2018-01-15
NO2887953T3 (https=) 2018-03-10
WO2014045296A2 (en) 2014-03-27
PT2887953T (pt) 2018-01-10
CA2881121A1 (en) 2014-03-27
WO2014045296A3 (en) 2014-10-23
EP2887953B1 (en) 2017-10-11
BR112015003198A2 (pt) 2017-10-10
EP3287138A1 (en) 2018-02-28
AU2013319737B2 (en) 2018-08-02

Similar Documents

Publication Publication Date Title
SI2887953T1 (en) IMPROVED DAPTOMICINE FORMATION FORMULATION
BR112013003045A2 (pt) composto e composição farmacêutica e respectivos usos, recipiente estéril e método para preparar composição farmacêutica para administração
CN102670497A (zh) 一种稳定的s-奥拉西坦注射用制剂及其制备方法
CL2012001336A1 (es) Composicion farmaceutica solida de daptomicina preparada por liofilizacion de una solucion acuosa que comprende daptomicina y al menos un excipiente seleccionado de glicina y un azucar no reductor con un ph de 6,5-7,5; producto farmaceutico; metodo de fabricacion; uso para tratar infecciones bacterianas.
CA2945201C (en) Vaccine compositions
BRPI0923326A2 (pt) Composto, composição farmacêutica, métodos para inibir girasse de dna bacteriana e/ou topisomerase iv bacteriana, para produzir um efeito antibacteriano em um animal de sangue quente, e para tratar uma infecção bacteriana, uso de um composto, e, processo para preparar um composto.
BR112013032974A2 (pt) "derivados de 1,6-diazabiciclo [3,2,1]-octan-7-ona, seus usos, e composições farmacêuticas".
AU2016204371A1 (en) Lyophilised and aqueous anti-CD40 antibody formulations
DK1506214T3 (da) 6-11 bicykliske ketolidderivater
WO2009139576A3 (ko) 신규 벤즈옥사졸로 치환된 피리딘 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 이상세포 성장 질환의 예방 및 치료용 약학적 조성물
MX2014011537A (es) Formulaciones parenterales para la administracion de antibioticos macrolidos.
DK2895187T1 (da) Daptomycinformuleringer og anvendelser deraf
AU2018322769A1 (en) Daptomycin formulations
CN101984968A (zh) 抗肿瘤剂替莫唑胺的药物制剂制备方法
RU2011130278A (ru) Новые противобактериальные средства для лечения грамположительных инфекций
JP2015526463A5 (https=)
WO2016098009A1 (en) Lyophilized injectable compositions of daptomycin
US20040229825A1 (en) Pharmaceutical composition for treatment of infection with drug resistant bacterium and disinfectant
DE60131441D1 (de) Verfahren zur formulierung antibiotischer verbindungen
CN103880930A (zh) 万古霉素类衍生物及其制备方法和药用用途
AU2006324315B2 (en) Veterinarian composition comprising an organic salt of levamisole in combination with at least one avermectine and/or milbemycine
CN103212113A (zh) 万古霉素阳离子脂质体复合纳米羟基磷灰石/壳聚糖/魔芋葡苷聚糖支架的制备方法
CN101732264B (zh) 一种头孢西酮钠冻干粉针剂
WO2007020505A3 (en) Medicinal forms of phospholipid preparations and methods for their preparation
CN104352491A (zh) 一种复方阿莫西林钠脂质体药物及其制备方法